Q-omics provides the consensus-scored FAM66D profile across patient tissues and cancer cell-line models. FAM66D expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM66D is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, FAM66D RNA expression shows 15,904 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, UCEC, and THYM as cancer lineages where FAM66D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM66D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM66D survival associations across molecular data types. FAM66D RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM66D RNA expression–survival associations across cancer types. High FAM66D expression shows unfavorable associations in DLBC and UCEC, but favorable associations in HNSC, BRCA, KIRC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM66D RNA expression.
This table summarizes FAM66D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM66D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM66D shows lower tumor expression in UCEC, BRCA, THCA, KIRC and STAD and higher tumor expression in CHOL. The UCEC box plot shows higher FAM66D RNA expression in normal versus tumor tissue (log2 FC = −0.766, t-test p < 0.001).
This table shows molecular features associated with FAM66D in patient tissues and cancer cell lines. In patient samples, FAM66D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM66D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
